Biologics and Biosimilars Market

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In Biologics and Biosimilars Market is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in Biologics and Biosimilars Market is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ?innovator? products, and can be manufactured when the original product's patent expires.

Biologics and Biosimilars Market contains market size and forecasts of Biologics and Biosimilars in global, including the following market information:

Global Biologics and Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Biologics and Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Biologics and Biosimilars companies in 2021 (%)

The global Biologics and Biosimilars market was valued at 198790 million in 2021 and is projected to reach US$ 277500 million by 2028, at a CAGR of 4.9% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Biologics and Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Biologics and Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biologics and Biosimilars Market Segment Percentages, by Type, 2021 (%)

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

Global Biologics and Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biologics and Biosimilars Market Segment Percentages, by Application, 2021 (%)

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

Global Biologics and Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biologics and Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Biologics and Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Biologics and Biosimilars revenues share in global market, 2021 (%)

Key companies Biologics and Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Biologics and Biosimilars sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Roche

Amgen

AbbVie

Sanofi-Aventis

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

3sbio

Changchun High Tech

CP Guojian

Biotech

Gelgen

Innovent

Dong Bao

Ganlee

United Laboratories